Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Also Secondary Endpoints in Phase III
The multicentric prospective PROSTAPROGRESS study on Ferumoxtran confirmed to meet also secondary endpoints. Post-hoc analysis showed elevated sensitivity and specificity data for metastatic lymph node lesions at levels surpassing the levels of current technologies.
Weiterlesen